FR2973248B1 - Gamma-butyrolactones 2,3-polysubstituees a visee therapeutique - Google Patents

Gamma-butyrolactones 2,3-polysubstituees a visee therapeutique

Info

Publication number
FR2973248B1
FR2973248B1 FR1152771A FR1152771A FR2973248B1 FR 2973248 B1 FR2973248 B1 FR 2973248B1 FR 1152771 A FR1152771 A FR 1152771A FR 1152771 A FR1152771 A FR 1152771A FR 2973248 B1 FR2973248 B1 FR 2973248B1
Authority
FR
France
Prior art keywords
butyrolactones
polysubstituted
gamma
vision
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1152771A
Other languages
English (en)
Other versions
FR2973248A1 (fr
Inventor
Gall Erwan Le
Eric Leonel
Floch Camille Le
Thierry Martens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eric Leonel Fr
Erwan Le Gall Fr
Thierry Martens Fr
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Paris Est Creteil Paris 12
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Paris Est Creteil Paris 12 filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1152771A priority Critical patent/FR2973248B1/fr
Publication of FR2973248A1 publication Critical patent/FR2973248A1/fr
Application granted granted Critical
Publication of FR2973248B1 publication Critical patent/FR2973248B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1152771A 2011-03-31 2011-03-31 Gamma-butyrolactones 2,3-polysubstituees a visee therapeutique Expired - Fee Related FR2973248B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1152771A FR2973248B1 (fr) 2011-03-31 2011-03-31 Gamma-butyrolactones 2,3-polysubstituees a visee therapeutique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1152771A FR2973248B1 (fr) 2011-03-31 2011-03-31 Gamma-butyrolactones 2,3-polysubstituees a visee therapeutique

Publications (2)

Publication Number Publication Date
FR2973248A1 FR2973248A1 (fr) 2012-10-05
FR2973248B1 true FR2973248B1 (fr) 2013-03-29

Family

ID=44548940

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1152771A Expired - Fee Related FR2973248B1 (fr) 2011-03-31 2011-03-31 Gamma-butyrolactones 2,3-polysubstituees a visee therapeutique

Country Status (1)

Country Link
FR (1) FR2973248B1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW499427B (en) * 1998-06-18 2002-08-21 Dev Center Biotechnology A alpha-methylene-3-di[(substituted)phenyl]methyl-gamma-butyrolactone, halogenated derivatives thereof, and anti-cancer compositions containing the same
TW200503738A (en) * 2003-07-16 2005-02-01 Tzu Chi Buddhist General Hospital Method for extracting antineoplastic components from bupleurum scorzonerifolium

Also Published As

Publication number Publication date
FR2973248A1 (fr) 2012-10-05

Similar Documents

Publication Publication Date Title
NO2022010I1 (no) ripretinib, or a pharmaceutically acceptable salt thereof
NO2023021I1 (no) Loncastuximab tesirine in all forms protected by the basic patent
NO2021034I1 (no) pemigatinib or a pharmaceutically acceptable salt thereof
LUC00083I2 (fr) Bictegravir or a pharmaceutically acceptable salt thereof, in particular bictegravir sodium
NO2021041I1 (no) remimazolam or a pharmaceutically acceptable salt thereof
BR112013024491A2 (pt) neuroestimulador.
DK2709667T3 (da) Bio-orthogonal lægemiddelaktivering
DK2594731T3 (da) Cementering under styret tryk
BR112013020613A2 (pt) autoinjetor
BR112013015783A2 (pt) autoinjetor.
BR112013030506A2 (pt) aparelho de exercício.
DK3384944T3 (da) Autoinjektor
DK2760886T3 (da) Immunocytokin-kombinationsterapi
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
FI20115876A0 (fi) Yhdistelmähoito
HK1192757A1 (zh) 取代的 -芳基- -苯基- -三嗪- -胺
PT2783256T (pt) Óculos terapêuticos
EP2768415A4 (fr) Photocoagulation avec gestion de point d'extrémité
ZA201401159B (en) Peg-interferon lambda 1 conjugates
BR302012005955S1 (pt) "configuração aplicada a cadeira"
BR302012001925S1 (pt) "configuração aplicada em calota"
FI20115640A0 (fi) Yhdistelmähoito
DK2500470T3 (da) Hoved-arbejdsvogn
FI20116047L (fi) Menetelmä terveyskortin hallinnoimiseksi
FR2973248B1 (fr) Gamma-butyrolactones 2,3-polysubstituees a visee therapeutique

Legal Events

Date Code Title Description
TQ Partial transmission of property

Owner name: THIERRY MARTENS, FR

Effective date: 20130220

Owner name: ERWAN LE GALL, FR

Effective date: 20130220

Owner name: ERIC LEONEL, FR

Effective date: 20130220

ST Notification of lapse

Effective date: 20151130